1. Home
  2. MNY vs SCYX Comparison

MNY vs SCYX Comparison

Compare MNY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNY
  • SCYX
  • Stock Information
  • Founded
  • MNY 2014
  • SCYX 1999
  • Country
  • MNY Singapore
  • SCYX United States
  • Employees
  • MNY N/A
  • SCYX N/A
  • Industry
  • MNY
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MNY
  • SCYX Health Care
  • Exchange
  • MNY Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • MNY 47.1M
  • SCYX 50.3M
  • IPO Year
  • MNY N/A
  • SCYX 2014
  • Fundamental
  • Price
  • MNY $1.07
  • SCYX $1.05
  • Analyst Decision
  • MNY
  • SCYX Buy
  • Analyst Count
  • MNY 0
  • SCYX 1
  • Target Price
  • MNY N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • MNY 144.2K
  • SCYX 174.1K
  • Earning Date
  • MNY 12-10-2024
  • SCYX 11-06-2024
  • Dividend Yield
  • MNY N/A
  • SCYX N/A
  • EPS Growth
  • MNY N/A
  • SCYX N/A
  • EPS
  • MNY N/A
  • SCYX N/A
  • Revenue
  • MNY $90,185,081.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • MNY $26.64
  • SCYX N/A
  • Revenue Next Year
  • MNY $25.46
  • SCYX $405.82
  • P/E Ratio
  • MNY N/A
  • SCYX N/A
  • Revenue Growth
  • MNY 24.60
  • SCYX N/A
  • 52 Week Low
  • MNY $0.85
  • SCYX $1.06
  • 52 Week High
  • MNY $3.46
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • MNY 40.01
  • SCYX 37.92
  • Support Level
  • MNY $1.02
  • SCYX $1.06
  • Resistance Level
  • MNY $1.13
  • SCYX $1.25
  • Average True Range (ATR)
  • MNY 0.07
  • SCYX 0.07
  • MACD
  • MNY -0.02
  • SCYX -0.01
  • Stochastic Oscillator
  • MNY 19.30
  • SCYX 17.65

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: